Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.

• Revenue in USD (TTM)0.00
• Net income in USD-37.52m
• Incorporated2006
• Employees10.00

• Location
  Sagimet Biosciences Inc155 BOVET RD., SUITE 303SAN MATEO 94402United StatesUSA
• Phone+1 (650) 561-8600
• Fax+1 (302) 730-1370
• Websitehttps://sagimet.com/